Drug Trial Radar · NCT05855200
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
892
Planned (sponsor's estimate)
Start
Aug 1, 2023
Primary completion
Mar 19, 2029
Study completion Mar 27, 2031
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
Conditions
- Colonic Neoplasms
- Neoplasms, Colon
Interventions
DostarlimabBiological
Dostarlimab will be administered.
CAPEOXDrug
CAPEOX will be administered.
FOLFOXDrug
FOLFOX will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 5 years
Locations
266 sites in 28 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Tucson, Arizona · Recruiting
GSK Investigational Site
Los Angeles, California · Recruiting
GSK Investigational Site
New Haven, Connecticut · Recruiting
GSK Investigational Site
Washington D.C., District of Columbia · Withdrawn
GSK Investigational Site
Deerfield Beach, Florida · Withdrawn
GSK Investigational Site
Fort Lauderdale, Florida · Withdrawn
GSK Investigational Site
Marietta, Georgia · Withdrawn
GSK Investigational Site
Chicago, Illinois · Recruiting
GSK Investigational Site
Chicago, Illinois · Recruiting
GSK Investigational Site
Chicago, Illinois · Withdrawn
GSK Investigational Site
Naperville, Illinois · Recruiting
GSK Investigational Site
Naperville, Illinois · Recruiting
GSK Investigational Site
Westwood, Kansas · Recruiting
GSK Investigational Site
Lexington, Kentucky · Withdrawn
GSK Investigational Site
Louisville, Kentucky · Withdrawn
GSK Investigational Site
Baton Rouge, Louisiana · Withdrawn
GSK Investigational Site
Bethesda, Maryland · Recruiting
GSK Investigational Site
Ann Arbor, Michigan · Withdrawn
GSK Investigational Site
Detroit, Michigan · Recruiting
GSK Investigational Site
Minneapolis, Minnesota · Recruiting
GSK Investigational Site
Joplin, Missouri · Withdrawn
GSK Investigational Site
St Louis, Missouri · Withdrawn
GSK Investigational Site
St Louis, Missouri · Withdrawn
GSK Investigational Site
Grand Island, Nebraska · Recruiting
GSK Investigational Site
Omaha, Nebraska · Recruiting
GSK Investigational Site
Omaha, Nebraska · Withdrawn
GSK Investigational Site
Lebanon, New Hampshire · Withdrawn
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
The Bronx, New York · Recruiting
GSK Investigational Site
Durham, North Carolina · Recruiting
GSK Investigational Site
Akron, Ohio · Recruiting
GSK Investigational Site
Cincinnati, Ohio · Recruiting
GSK Investigational Site
Cleveland, Ohio · Withdrawn
GSK Investigational Site
Cleveland, Ohio · Withdrawn
GSK Investigational Site
Cleveland, Ohio · Withdrawn
GSK Investigational Site
Oklahoma City, Oklahoma · Withdrawn
GSK Investigational Site
Oklahoma City, Oklahoma · Withdrawn
Showing 40 of 266 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.